ONL Therapeutics Inc. is developing Met12, a small peptide inhibitor that uses a novel mechanism to attack Fas receptor apoptosis, which has a key role in retinal detachment and AMD, CEO John Freshley reported. The drug targets the pathway activated in Fas-mediated apoptosis, Freshley said. Fas is an antigen encoded to the tumor necrosis factor receptor superfamily member 6 (TNFRSF6) gene.
Mr. Freshley has almost 20 years experience in leadership roles of start-up companies within both the life science and technology sectors. His expertise spans the assembly of multi-disciplinary leadership teams, product and business strategy development, partnership development, and venture capital fundraising.